sponsored links

Glaxo defiende manejo de los riesgos cardiacos de Avandia (AP)

Sponsored Links

AP – GlaxoSmithKline dijo el miércoles un informe del Senado criticar su manejo de los riesgos del corazón con su medicamento para la diabetes Avandia “y distorsiona erróneamente el” registro de la empresa.

View full post on Yahoo! News: Health News


Sponsored Links
You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

AddThis Social Bookmark Button

Leave a Reply

You must be logged in to post a comment.